恩他卡朋联合卡比多巴治疗帕金森病的临床效果  

Clinical effect of entacapone combined with carbidopa in the treatment of Parkinson′s disease

作　　者：吴晓燕 陈遥 陈晓仪 刘慧[2] WU Xiaoyan;CHEN Yao;CHEN Xiaoyi;LIU Hui(Department of Pharmacy,Zhongshan Torch Development Zone People′s Hospital,Guangdong Province,Zhongshan 528437,China;不详)

机构地区：[1]中山火炬开发区人民医院药学部,广东省中山市528437 [2]暨南大学附属第一医院药学部,广州市510630

出　　处：《临床合理用药杂志》2024年第15期12-15,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察恩他卡朋联合卡比多巴治疗帕金森病(PD)的效果。方法选取2020年7月—2022年12月中山火炬开发区人民医院收治的PD患者100例,按随机数字表法分为单一组(n=50)和联合组(n=50)。单一组给予复方卡比多巴片治疗,联合组在单一组基础上加用恩他卡朋片治疗,2组均治疗3个月。比较2组临床疗效,治疗前后实验室指标[β淀粉样蛋白1-42(Aβ1-42)、尿酸(UA)、胱抑素C(CysC)、表皮生长因子(EGF)]、相关量表评分[统一帕金森病评定量表(UPDRS)、蒙特利尔认知评估量表(MoCA)、日常生活活动能力量表(ADL)],不良反应。结果联合组总有效率为92.00%,高于单一组的76.00%(χ^(2)=4.762,P=0.029)。治疗3个月后,2组血清Aβ1-42、CysC水平低于治疗前,血清UA、EGF水平高于治疗前,且联合组下降/升高幅度大于单一组(P<0.05或P<0.01);2组UPDRS评分低于治疗前,MoCA、ADL评分高于治疗前,且联合组降低/升高幅度大于单一组(P均<0.01)。联合组不良反应总发生率为16.00%,低于单一组的40.00%(χ^(2)=7.143,P=0.008)。结论恩他卡朋联合卡比多巴治疗PD可发挥协同增效,可有效控制病情进展,调节机体血清生物标志物水平,改善认知功能,提高患者日常生活活动能力,且安全性较高。Objective To explore the effect of entacapone combined with carbidopa in the treatment of PD.Methods A total of 100 cases of PD patients admitted to Zhongshan Torch Development Zone People′s Hospital from July 2020 to December 2022 were selected and divided into the single group(n=50)and the combined group(n=50)according to the random number table method.The single group was given compound carbidopa tablets,and the combined group was combined with entacapone tablets on the basis of the single group,and both groups were treated for 3 months.Clinical efficacy,laboratory indexes(Aβ1-42,UA,CysC,EGF),relevant scales scores(UPDRS,MoCA,ADL)before and after treatment,and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the combined group was 92.00%,which was higher than 76.00%in the single group(χ^(2)=4.762,P=0.029).After 3 months of treatment,serum Aβ1-42 and CysC levels of the two groups were lower than those before treatment,serum UA and EGF levels were higher than those before treatment,and the decreased/increased amplitude of the combined group were greater than those of the single group(P<0.05 or P<0.01);UPDRS score of the two groups was lower than that before treatment,and scores of MoCA and ADL were higher than those before treatment,and the decreased/increased amplitude of the combined group were greater than those of the single group(P<0.01).The overall incidence of adverse reactions was 16.00%in the combined group,which was lower than 40.00%in the single group(χ^(2)=7.143,P=0.008).Conclusion Entacapone combined with carbidopa can enhance curative effect in the treatment of PD patients,it can effectively control the progression of the disease,regulate the serum biomarkers,improve the cognitive function and promote the ability of daily living activities of patients,and with higher safety.

关 键 词：帕金森病 恩他卡朋 卡比多巴 血清生物标志物 认知功能 

分 类 号：R969[医药卫生—药理学] R742.5[医药卫生—药学]